Inozyme Pharma - INZY Net earnings per one share for the last twelve months

Inozyme Pharma Inc. (INZY) - corporate logo

Historical EPS YoY TTM dynamics demonstrate the impact of supply chain disruptions on Inozyme Pharma, Inc. (INZY). The current value of 33.60 serves as a baseline performance metric, which relies on the success of clinical trials for enzyme replacement therapy targeting orphan diseases. Meanwhile, environmental stability is ensured by medical sanctions exemptions and strict oversight from the FDA and EMA regulators.

INZY: Inozyme Pharma Net earnings per share for the last 12 months 02/11/2024 - 02/20/2024

Inozyme Pharma - analytical breakdowns and key metrics (INZY)

- issuer market value details:
Fundamental company valuation:INZY - Inozyme
Brand item of inozyme.com

This indicator determines the net income growth rate per share over the last twelve months relative to the previous year. The metric aggregates operational efficiency, allowing for an assessment of return on equity dynamics through the year-over-year change in EPS (TTM). Rising values signal a strengthening of the asset's fundamental value. For Inozyme Pharma, Inc. (INZY), negative trends at the R&D stage reflect high development costs; however, a future patent for the treatment of rare diseases could sharply reverse this vector due to the high margins of exclusive drugs.

Competitor analysis

Earnings per one share for the last 12 months VRTX|ALNY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Insmed Inc (INSM)|UTHR (United Therapeutics Corporation) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BMRN (BioMarin)|Net earnings per share for the last 12 months BBIO (BridgeBio)|BGM: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Cogent Biosciences, Inc. COGT|XERS (Xeris Biopharma Inc) - Earnings per one share for the last 12 months|Keros Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ARCT (Arcturus Therapeutics)|ETON: Net earnings per share (EPS TTM)|Kamada Ltd (KMDA) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Fulcrum Tx|ABEO: Earnings per share for the trailing year|Earnings per share for the last twelve months Mereo BioPharma Group (MREO)|Net earnings per share (EPS TTM) protalix.com (PLX)|Net earnings per share (EPS TTM) PLRX (Pliant Therapeutics Inc)|Net earnings per share (EPS TTM) Applied Therapeutics APLT|RNTX - Earnings per share for the last twelve months|Net earnings per share for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Net earnings per share for the last 12 months|Chemomab Therapeutics Ltd - Earnings per share for the trailing year|Net earnings per share for the last 12 months SRXH|Earnings per share for the last twelve months PLRZ|Net earnings per share (EPS TTM) AEZS|Earnings per share for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)